James Battiste to Gliosarcoma
This is a "connection" page, showing publications James Battiste has written about Gliosarcoma.
Connection Strength
0.174
-
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.
Score: 0.174